Bo Ahrn

List of Publications by Year in Descending Order

425 papers	20,609 citations	74 h-index	126 g-index
442 ext. papers	22,153 ext. citations	6.2 avg, IF	7.25 L-index

#	Paper	IF	Citations
425	Temporal Patterns of Glucagon and Its Relationships with Glucose and Insulin following Ingestion of Different Classes of Macronutrients.. *Nutrients*, **2022**, 14,	6.7	2
424	Mathematical Model of Glucagon Kinetics for the Assessment of Insulin-Mediated Glucagon Inhibition During an Oral Glucose Tolerance Test. *Frontiers in Endocrinology*, **2021**, 12, 611147	5.7	4
423	Glucose-lowering action through targeting islet dysfunction in type 2 diabetes: Focus on dipeptidyl peptidase-4 inhibition. *Journal of Diabetes Investigation*, **2021**, 12, 1128-1135	3.9	2
422	The Insulin Response to Oral Glucose in GIP and GLP-1 Receptor Knockout Mice: Review of the Literature and Stepwise Glucose Dose Response Studies in Female Mice. *Frontiers in Endocrinology*, **2021**, 12, 665537	5.7	2
421	Impact of Incretin Hormone Receptors on Insulin-Independent Glucose Disposal in Model Experiments in Mice. *Frontiers in Endocrinology*, **2021**, 12, 680153	5.7	2
420	The mediation by GLP-1 receptors of glucagon-induced insulin secretion revisited in GLP-1 receptor knockout mice. *Peptides*, **2021**, 135, 170434	3.8	3
419	Glucose effectiveness: Lessons from studies on insulin-independent glucose clearance in mice. *Journal of Diabetes Investigation*, **2021**, 12, 675-685	3.9	6
418	Hepatic and Extrahepatic Insulin Clearance in Mice with Double Deletion of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Receptors. *Biomedicines*, **2021**, 9,	4.8	1
417	Glucagon-like peptide-1 and beta cell glucose sensitivity - a glucose ramp study in mice. *Peptides*, **2021**, 146, 170650	3.8	0
416	The Incretin Effect in Female Mice With Double Deletion of GLP-1 and GIP Receptors. *Journal of the Endocrine Society*, **2020**, 4, bvz036	0.4	4
415	Persistent whole day meal effects of three dipeptidyl peptidase-4 inhibitors on glycaemia and hormonal responses in metformin-treated type 2 diabetes. *Diabetes, Obesity and Metabolism*, **2020**, 22, 590-598	6.7	7
414	Consequences on islet and incretin hormone responses to dinner by omission of lunch in healthy men. *Endocrinology, Diabetes and Metabolism*, **2020**, 3, e00141	2.7	
413	Islet adaptation in GIP receptor knockout mice. *Peptides*, **2020**, 125, 170152	3.8	2
412	Reduction in Glycated Hemoglobin and Daily Insulin Dose Alongside Circadian Clock Upregulation in Patients With Type 2 Diabetes Consuming a Three-Meal Diet: A Randomized Clinical Trial. *Diabetes Care*, **2019**, 42, 2171-2180	14.6	31
411	Effect of Liraglutide on Times in Glycaemic Ranges as Assessed by CGM for Type 2 Diabetes Patients Treated With Multiple Daily Insulin Injections. *Diabetes Therapy*, **2019**, 10, 2115-2130	3.6	9
410	Effect of liraglutide on anthropometric measurements, sagittal abdominal diameter and adiponectin levels in people with type 2 diabetes treated with multiple daily insulin injections: evaluations from a randomized trial (MDI-liraglutide study 5). *Obesity Science and Practice*, **2019**, 5, 130-140	2.6	6
409	Insulin and incretin hormone responses to rapid versus slow ingestion of a standardized solid breakfast in healthy subjects. *Endocrinology, Diabetes and Metabolism*, **2019**, 2, e00056	2.7	4

408	Glucagon-like peptide-1 receptor agonists for type 2 diabetes: A rational drug development. *Journal of Diabetes Investigation*, **2019**, 10, 196-201	3.9	23
407	Incretin-based medications (GLP-1 receptor agonists, DPP-4 inhibitors) as a means to avoid hypoglycaemic episodes. *Metabolism: Clinical and Experimental*, **2019**, 99, 25-31	12.7	8
406	DPP-4 Inhibition and the Path to Clinical Proof. *Frontiers in Endocrinology*, **2019**, 10, 376	5.7	36
405	Glucagon and insulin secretion, insulin clearance, and fasting glucose in GIP receptor and GLP-1 receptor knockout mice. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2019**, 316, R27-R37	3.2	15
404	Different glucagon effects during DPP-4 inhibition versus SGLT-2 inhibition in metformin-treated type 2 diabetes patients. *Diabetes, Obesity and Metabolism*, **2018**, 20, 1652-1658	6.7	8
403	Effects on the glucagon response to hypoglycaemia during DPP-4 inhibition in elderly subjects with type 2 diabetes: A randomized, placebo-controlled study. *Diabetes, Obesity and Metabolism*, **2018**, 20, 1911-1920	6.7	2
402	DPP-4 is expressed in human pancreatic beta cells and its direct inhibition improves beta cell function and survival in type 2 diabetes. *Molecular and Cellular Endocrinology*, **2018**, 473, 186-193	4.4	31
401	Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3). *BMJ Open Diabetes Research and Care*, **2018**, 6, e000464	4.5	13
400	Increased insulin clearance in mice with double deletion of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2018**, 314, R639-R646	3.2	11
399	Effect of single-dose DPP-4 inhibitor sitagliptin on □cell function and incretin hormone secretion after meal ingestion in healthy volunteers and drug-na□ve, well-controlled type 2 diabetes subjects. *Diabetes, Obesity and Metabolism*, **2018**, 20, 1080-1085	6.7	9
398	Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. *Diabetes, Obesity and Metabolism*, **2018** , 20, 2210-2219	6.7	44
397	Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials. *Diabetes Research and Clinical Practice*, **2017**, 126, 230-239	7.4	16
396	Glucagon-like peptide-1 and glucose-dependent insulinotropic peptide: effects alone and in combination on insulin secretion and glucose disappearance in mice. *Physiological Reports*, **2017**, 5, e13280	2.6	13
395	Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus: Results over 52 weeks. *Journal of Diabetes and Its Complications*, **2017**, 31, 1283-1285	3.2	7
394	Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. *Lancet Diabetes and Endocrinology,the*, **2017**, 5, 341-354	18.1	189
393	Glucagon increases insulin levels by stimulating insulin secretion without effect on insulin clearance in mice. *Peptides*, **2017**, 88, 74-79	3.8	17
392	Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open-label, 2-arm parallel comparative, exploratory trial. *Diabetes, Obesity and Metabolism*, **2017**, 19, 442-447	6.7	20
391	Alain Ktorza, PhD. *Diabetes, Obesity and Metabolism*, **2017**, 19 Suppl 1, 3	6.7	

390	The Vildagliptin Experience - 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration. *European Endocrinology*, **2017**, 13, 56-61	3.4	3
389	Influences of Breakfast on Clock Gene Expression and Postprandial Glycemia in Healthy Individuals and Individuals With Diabetes: A Randomized Clinical Trial. *Diabetes Care*, **2017**, 40, 1573-1579	14.6	70
388	Diurnal glucose exposure profiles of patients treated with lixisenatide before breakfast or the main meal of the day: An analysis using continuous glucose monitoring. *Diabetes/Metabolism Research and Reviews*, **2017**, 33, e2879	7.5	7
387	Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy. *Diabetes Research and Clinical Practice*, **2017**, 131, 49-60	7.4	16
386	High-energy breakfast based on whey protein reduces body weight, postprandial glycemia and HbA in Type 2 diabetes. *Journal of Nutritional Biochemistry*, **2017**, 49, 1-7	6.3	31
385	Extrapancreatic contribution to glucose regulation by dipeptidyl peptidase 4 inhibition. *Cardiovascular Endocrinology*, **2016**, 5, 82-85		
384	Incretin hormone receptors are required for normal beta cell development and function in female mice. *Peptides*, **2016**, 79, 58-65	3.8	7
383	Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse cell function in the GetGoal-M and GetGoal-S trials. *Journal of Diabetes and Its Complications*, **2016**, 30, 1385-92	3.2	13
382	CART is overexpressed in human type 2 diabetic islets and inhibits glucagon secretion and increases insulin secretion. *Diabetologia*, **2016**, 59, 1928-37	10.3	19
381	Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism. *Diabetologia*, **2016**, 59, 907-17	10.3	44
380	Evidence for time dependent variation of glucagon secretion in mice. *Peptides*, **2016**, 76, 102-7	3.8	2
379	Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis. *Canadian Journal of Diabetes*, **2016**, 40, 50-7	2.1	20
378	Effect of the GLP-1 Receptor Agonist Lixisenatide on Counterregulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes. *Diabetes Care*, **2016**, 39, 242-9	14.6	11
377	Estimation of the Relative Contribution of Postprandial Glucose Exposure to Average Total Glucose Exposure in Subjects with Type 2 Diabetes. *International Journal of Endocrinology*, **2016**, 2016, 3452898	2.7	
376	Evidence for neural contribution to islet effects of DPP-4 inhibition in mice. *European Journal of Pharmacology*, **2016**, 780, 46-52	5.3	8
375	Enhanced insulin sensitivity mediated by adipose tissue browning perturbs islet morphology and hormone secretion in response to autonomic nervous activation in female mice. *American Journal of Physiology - Endocrinology and Metabolism*, **2016**, 310, E81-90	6	
374	Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis. *Diabetes Therapy*, **2016**, 7, 583-90	3.6	4
373	Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial. *Diabetes Care*, **2016**, 39, 1693-701	14.6	98

372	Insulin Resistance Is Accompanied by Increased Fasting Glucagon and Delayed Glucagon Suppression in Individuals With Normal and Impaired Glucose Regulation. *Diabetes*, **2016**, 65, 3473-3481	10.9	93
371	Mixed meal ingestion diminishes glucose excursion in comparison with glucose ingestion via several adaptive mechanisms in people with and without type 2 diabetes. *Diabetes, Obesity and Metabolism* , **2016**, 18, 24-33	6.7	15
370	DPP-4 inhibition contributes to the prevention of hypoglycaemia through a GIP-glucagon counterregulatory axis in mice. *Diabetologia*, **2015**, 58, 1091-9	10.3	28
369	High-energy breakfast with low-energy dinner decreases overall daily hyperglycaemia in type 2 diabetic patients: a randomised clinical trial. *Diabetologia*, **2015**, 58, 912-9	10.3	70
368	Fasting until noon triggers increased postprandial hyperglycemia and impaired insulin response after lunch and dinner in individuals with type 2 diabetes: a randomized clinical trial. *Diabetes Care*, **2015**, 38, 1820-6	14.6	83
367	Glucagon and GLP-1 exhibit no synergistic enhancement of glucose-stimulated insulin secretion in mice. *Peptides*, **2015**, 71, 66-71	3.8	4
366	Creative use of novel glucose-lowering drugs for type 2 diabetes: where will we head in the next 50 years?. *Diabetologia*, **2015**, 58, 1740-4	10.3	8
365	Neuropeptides and islet hormone secretion **2015**, 125-135		
364	Glucagon--Early breakthroughs and recent discoveries. *Peptides*, **2015**, 67, 74-81	3.8	63
363	Deciphering the Hypoglycemic Glucagon Response: Development of a Graded Hyperinsulinemic Hypoglycemic Clamp Technique in Female Mice. *Endocrinology*, **2015**, 156, 3866-71	4.8	6
362	Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial). *BMJ, The*, **2015**, 351, h5364	5.9	44
361	Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin. *International Journal of Endocrinology*, **2015**, 2015, 484231	2.7	9
360	Hepato-incretin function of GLP-1: novel concept and target in type 1 diabetes. *Diabetes*, **2015**, 64, 715-7	10.9	7
359	Incretin effect after oral amino acid ingestion in humans. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, 1172-6	5.6	42
358	Physiological aspects of the combination of insulin and GLP-1 in the regulation of blood glucose control. *Diabetes and Metabolism*, **2015**, 41, 6S3-6S8	5.4	4
357	Incretin and islet hormone responses to meals of increasing size in healthy subjects. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, 561-8	5.6	19
356	Four-Year Durability of Initial Combination Therapy with Sitagliptin and Metformin in Patients with Type 2 Diabetes in Clinical Practice; COSMIC Study. *PLoS ONE*, **2015**, 10, e0129477	3.7	15
355	Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies. *Diabetologia*, **2014**, 57, 1304-7	10.3	38

354	Fibroblast growth factor 21 (FGF21) and glucagon-like peptide 1 contribute to diabetes resistance in glucagon receptor-deficient mice. *Diabetes*, **2014**, 63, 101-10	0.9	54
353	Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. *Diabetes Care*, **2014**, 37, 2317-25	14.6	173
352	Conditional glucagon receptor overexpression has multi-faceted consequences for beta-cell function. *Metabolism: Clinical and Experimental*, **2014**, 63, 1568-76	12.7	8
351	Incretin, insulinotropic and glucose-lowering effects of whey protein pre-load in type 2 diabetes: a randomised clinical trial. *Diabetologia*, **2014**, 57, 1807-11	10.3	95
350	Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors. *Diabetes*, **2014**, 63, 2196-202	0.9	74
349	Glucagon clearance is regulated by nutritional state: evidence from experimental studies in mice. *Diabetologia*, **2014**, 57, 801-8	10.3	7
348	Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes. *Diabetologia*, **2014**, 57, 1876-83	10.3	57
347	GLP-1 released to the mesenteric lymph duct in mice: effects of glucose and fat. *Regulatory Peptides*, **2014**, 189, 40-5		18
346	Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes. *Diabetes, Obesity and Metabolism*, **2014**, 16, 812-8	6.7	42
345	Equal improvement in glycaemia with lixisenatide given before breakfast or the main meal of the day. *Journal of Diabetes and Its Complications*, **2014**, 28, 735-41	3.2	12
344	Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?. *Diabetes Therapy*, **2014**, 5, 459-69	3.6	10
343	Dipeptidyl peptidase-4 (DPP-4): Localization and activity in human and rodent islets. *Biochemical and Biophysical Research Communications*, **2014**, 453, 398-404	3.4	21
342	Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials. *Diabetes, Obesity and Metabolism*, **2014**, 16, 861-8	6.7	21
341	HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. *Diabetes Care*, **2014**, 37, 2141-8	14.6	166
340	Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes. *World Journal of Diabetes*, **2014**, 5, 40-51	4.7	42
339	Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model. *Diabetologia*, **2013**, 56, 1752-60	10.3	52
338	Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. *Diabetes, Obesity and Metabolism*, **2013**, 15, 112-20	6.7	195
337	Incretin dysfunction in type 2 diabetes: clinical impact and future perspectives. *Diabetes and Metabolism*, **2013**, 39, 195-201	5.4	45

336	Glucose-lowering effect of the DPP-4 inhibitor sitagliptin after glucose and non-glucose macronutrient ingestion in non-diabetic subjects. *Diabetes, Obesity and Metabolism*, **2013**, 15, 531-7	6.7	26
335	Upregulated insulin secretion in insulin-resistant mice: evidence of increased islet GLP1 receptor levels and GPR119-activated GLP1 secretion. *Endocrine Connections*, **2013**, 2, 69-78	3.5	23
334	GLP-1 receptor agonists in the treatment of Type 2 diabetes. *Diabetes Management*, **2013**, 3, 401-413	0	12
333	Methods and models for metabolic assessment in mice. *Journal of Diabetes Research*, **2013**, 2013, 986906	3.9	37
332	Incretin therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. *European Diabetes Nursing*, **2013**, 10, 31-36		8
331	Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). *Diabetes Care*, **2013**, 36, 2543-50	14.6	129
330	Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. *Vascular Health and Risk Management*, **2013**, 9, 155-63	4.4	119
329	Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin. *Vascular Health and Risk Management*, **2013**, 9, 57-64	4.4	23
328	Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. *Diabetes, Obesity and Metabolism*, **2012**, 14, 762-7	6.7	147
327	DPP-4 inhibition and islet function. *Journal of Diabetes Investigation*, **2012**, 3, 3-10	3.9	15
326	Synergism by individual macronutrients explains the marked early GLP-1 and islet hormone responses to mixed meal challenge in mice. *Regulatory Peptides*, **2012**, 178, 29-35		23
325	Plasma lipid fatty acid composition, desaturase activities and insulin sensitivity in Amerindian women. *Nutrition, Metabolism and Cardiovascular Diseases*, **2012**, 22, 176-81	4.5	11
324	Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 3799-806	5.6	74
323	Islet nerves in focus--defining their neurobiological and clinical role. *Diabetologia*, **2012**, 55, 3152-4	10.3	22
322	Vildagliptin: a DPP-4 inhibitor for the treatment of Type 2 diabetes. *Diabetes Management*, **2012**, 2, 453-464	0	2
321	Differential development of glucose intolerance and pancreatic islet adaptation in multiple diet induced obesity models. *Nutrients*, **2012**, 4, 1367-81	6.7	31
320	Using albumin to improve the therapeutic properties of diabetes treatments. *Diabetes, Obesity and Metabolism*, **2012**, 14, 121-9	6.7	8
319	Switching from high-fat to low-fat diet normalizes glucose metabolism and improves glucose-stimulated insulin secretion and insulin sensitivity but not body weight in C57BL/6J mice. *Pancreas*, **2012**, 41, 253-7	2.6	11

318	Inhibition of Dipeptidyl Peptidase-4 (DPP-4): A Target to Treat Type 2 Diabetes. *Current Enzyme Inhibition*, **2012**, 7, 205-217	0.5	4
317	Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. *Diabetes, Obesity and Metabolism*, **2011**, 13, 193-203	6.7	45
316	Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. *Diabetes, Obesity and Metabolism*, **2011**, 13, 775-83	6.7	114
315	Dissociated incretin hormone response to protein versus fat ingestion in obese subjects. *Diabetes, Obesity and Metabolism*, **2011**, 13, 863-5	6.7	15
314	The future of incretin-based therapy: novel avenues--novel targets. *Diabetes, Obesity and Metabolism*, **2011**, 13 Suppl 1, 158-66	6.7	48
313	GLP-1 for type 2 diabetes. *Experimental Cell Research*, **2011**, 317, 1239-45	4.2	64
312	Chronic glucokinase activation reduces glycaemia and improves glucose tolerance in high-fat diet fed mice. *European Journal of Pharmacology*, **2011**, 663, 80-6	5.3	25
311	Are sulfonylureas less desirable than DPP-4 inhibitors as add-on to metformin in the treatment of type 2 diabetes?. *Current Diabetes Reports*, **2011**, 11, 83-90	5.6	20
310	Reply to the letter by P. Guillausseau Regarding Sulfonylureas or Dipeptidyl Peptidase (DPP-4) Inhibitors in the Management of Type 2 Diabetes: Debate Is Not Yet Closed *Current Diabetes Reports*, **2011**, 11, 463-463	5.6	
309	The dynamic incretin adaptation and type 2 diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 620-2	5.6	5
308	Effects of increasing doses of glucagon-like peptide-1 on insulin-releasing phases during intravenous glucose administration in mice. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2011**, 300, R1126-33	3.2	9
307	Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 2519-24	5.6	131
306	Physiology of incretins in health and disease. *Review of Diabetic Studies*, **2011**, 8, 293-306	3.6	83
305	Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. *Diabetes, Obesity and Metabolism*, **2010**, 12, 780-9	6.7	163
304	Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, **2010**, Volume 3, 31-41	3.4	14
303	Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. *Diabetes Care*, **2010**, 33, 730-2	14.6	74
302	Increased cell volume in mice fed a high-fat diet: a dynamic study over 12 months. *Islets*, **2010**, 2, 353-6	2	61
301	Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 872-8	5.6	106

300	Incretin hormone secretion over the day. *Vitamins and Hormones*, **2010**, 84, 203-20	2.5	34
299	Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, **2010**, 3, 31-41	3.4	31
298	Dissociated effects of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide-1 on beta-cell secretion and insulin clearance in mice. *Metabolism: Clinical and Experimental*, **2010**, 59, 988-92	12.7	13
297	Disassociated relation between plasma tumor necrosis factor-alpha, interleukin-6 and increased body weight in Amerindian women: A long-term prospective study of natural body weight variation and impaired glucose tolerance. *Diabetology and Metabolic Syndrome*, **2010**, 2, 38	5.6	3
296	Improved insulin sensitivity and islet function after PPARdelta activation in diabetic db/db mice. *European Journal of Pharmacology*, **2010**, 626, 297-305	5.3	34
295	Study on administration of 1,5-anhydro-D-fructose in C57BL/6J mice challenged with high-fat diet. *BMC Endocrine Disorders*, **2010**, 10, 17	3.3	4
294	Reappraisal of the intravenous glucose tolerance index for a simple assessment of insulin sensitivity in mice. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2009**, 296, R1316-24	3.2	19
293	Beta- and alpha-cell dysfunction in subjects developing impaired glucose tolerance: outcome of a 12-year prospective study in postmenopausal Caucasian women. *Diabetes*, **2009**, 58, 726-31	0.9	50
292	Differential islet and incretin hormone responses in morning versus afternoon after standardized meal in healthy men. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 2887-92	5.6	58
291	Altered glucose tolerance in women with deliberate self-harm. *Psychoneuroendocrinology*, **2009**, 34, 878-83	5	6
290	Effects of conjugated linoleic acid plus n-3 polyunsaturated fatty acids on insulin secretion and estimated insulin sensitivity in men. *European Journal of Clinical Nutrition*, **2009**, 63, 778-86	5.2	22
289	Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. *Nature Reviews Drug Discovery*, **2009**, 8, 369-85	64.1	323
288	MODULATION OF FASTED AND POSTPRANDIAL PLASMA LIPIDS IN HEALTHY VOLUNTEERS BY A DIETARY MIXTURE OF OMEGA-3 FATTY ACIDS AND CONJUGATED LINOLEIC ACID. *Journal of Food Lipids*, **2009**, 16, 499-513		2
287	Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. *Diabetes, Obesity and Metabolism*, **2009**, 11, 157-66	6.7	231
286	Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 1236-43	5.6	164
285	DPP-4 inhibitors. *Insulin*, **2009**, 4, 15-31		6
284	Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events. *Best Practice and Research in Clinical Endocrinology and Metabolism*, **2009**, 23, 487-98	6.5	82
283	Dissociated incretin response to oral glucose at 1 year after restrictive vs. malabsorptive bariatric surgery. *Diabetes, Obesity and Metabolism*, **2009**, 11, 1027-33	6.7	10

282	Effect of a conjugated linoleic acid and omega-3 fatty acid mixture on body composition and adiponectin. *Obesity*, **2008**, 16, 1019-24	8	57
281	Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes. *Expert Opinion on Emerging Drugs*, **2008**, 13, 593-607	3.7	71
280	Disturbed alpha-cell function in mice with beta-cell specific overexpression of human islet amyloid polypeptide. *Experimental Diabetes Research*, **2008**, 2008, 304513		6
279	Incretin and islet hormonal responses to fat and protein ingestion in healthy men. *American Journal of Physiology - Endocrinology and Metabolism*, **2008**, 295, E779-84	6	133
278	Durable islet effects on insulin secretion and protein kinase A expression following exendin-4 treatment of high-fat diet-fed mice. *Journal of Molecular Endocrinology*, **2008**, 40, 93-100	4.5	5
277	The augmenting effect on insulin secretion by oral versus intravenous glucose is exaggerated by high-fat diet in mice. *Journal of Endocrinology*, **2008**, 197, 181-7	4.7	29
276	Vildagliptin: novel pharmacological approach to treat Type 2 diabetes. *Therapy: Open Access in Clinical Medicine*, **2008**, 5, 79-90		5
275	Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin. *Vascular Health and Risk Management*, **2008**, 4, 383-94	4.4	55
274	Evidence that autonomic mechanisms contribute to the adaptive increase in insulin secretion during dexamethasone-induced insulin resistance in humans. *Diabetologia*, **2008**, 51, 1018-24	10.3	18
273	Role of pituitary adenylate cyclase-activating polypeptide in the pancreatic endocrine system. *Annals of the New York Academy of Sciences*, **2008**, 1144, 28-35	6.5	30
272	The islet enhancer vildagliptin: mechanisms of improved glucose metabolism. *International Journal of Clinical Practice*, **2008**, 62, 8-14	2.9	49
271	Clinical measures of islet function: usefulness to characterize defects in diabetes. *Current Diabetes Reviews*, **2008**, 4, 129-45	2.7	21
270	Temporal and dietary fat content-dependent islet adaptation to high-fat feeding-induced glucose intolerance in mice. *Metabolism: Clinical and Experimental*, **2007**, 56, 122-8	12.7	36
269	G-protein-coupled receptors and islet function-implications for treatment of type 2 diabetes **2007**, 116, 437-48		128
268	Glucagon receptor antagonism improves islet function in mice with insulin resistance induced by a high-fat diet. *Diabetologia*, **2007**, 50, 1453-62	10.3	54
267	A Palaeolithic diet improves glucose tolerance more than a Mediterranean-like diet in individuals with ischaemic heart disease. *Diabetologia*, **2007**, 50, 1795-1807	10.3	190
266	GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors. *Current Diabetes Reports*, **2007**, 7, 340-7	5.6	36
265	Insulin secretion and insulin sensitivity in relation to fasting glucose in healthy subjects. *Diabetes Care*, **2007**, 30, 644-8	14.6	16

264	Glucagon-like peptide-1 accelerates the onset of insulin action on glucose disappearance in mice. *American Journal of Physiology - Endocrinology and Metabolism*, **2007**, 292, E1808-14	6	9
263	Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. *Hormone and Metabolic Research*, **2007**, 39, 826-9	3.1	37
262	Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. *Diabetes Care*, **2007**, 30, 1344-50	14.6	160
261	DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide. *Regulatory Peptides*, **2007**, 143, 97-103		37
260	Role of VIP and PACAP in islet function. *Peptides*, **2007**, 28, 1805-13	3.8	67
259	GPR40 is expressed in glucagon producing cells and affects glucagon secretion. *Biochemical and Biophysical Research Communications*, **2007**, 354, 240-5	3.4	81
258	DPP-4 inhibitors. *Best Practice and Research in Clinical Endocrinology and Metabolism*, **2007**, 21, 517-33	6.5	133
257	Omega-3 fatty acids and other polyunsaturated fatty acids and weight control **2007**, 281-304		1
256	Glucagon secretion in relation to insulin sensitivity in healthy subjects. *Diabetologia*, **2006**, 49, 117-22	10.3	27
255	Glucose-induced incretin hormone release and inactivation are differently modulated by oral fat and protein in mice. *Endocrinology*, **2006**, 147, 3173-80	4.8	104
254	Insulin secretion after dietary supplementation with conjugated linoleic acids and n-3 polyunsaturated fatty acids in normal and insulin-resistant mice. *American Journal of Physiology - Endocrinology and Metabolism*, **2006**, 290, E347-54	6	38
253	Early and rapid development of insulin resistance, islet dysfunction and glucose intolerance after high-fat feeding in mice overexpressing phosphodiesterase 3B. *Journal of Endocrinology*, **2006**, 189, 629-41	4.7	20
252	Glucagon receptor knockout mice display increased insulin sensitivity and impaired beta-cell function. *Diabetes*, **2006**, 55, 3463-9	0.9	96
251	Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties. *Expert Opinion on Investigational Drugs*, **2006**, 15, 431-42	5.9	67
250	Down-regulation of apolipoprotein M expression is mediated by phosphatidylinositol 3-kinase in HepG2 cells. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2006**, 1761, 256-60	5	26
249	Suppression of apolipoprotein M expression and secretion in alloxan-diabetic mouse: Partial reversal by insulin. *Biochemical and Biophysical Research Communications*, **2006**, 342, 1174-7	3.4	31
248	The insulin response to gastric glucose is reduced in PAC1 and GRP receptor gene deleted mice. *Nutrition, Metabolism and Cardiovascular Diseases*, **2006**, 16 Suppl 1, S17-21	4.5	3
247	Serum cholesteryl fatty acid composition and plasma glucose concentrations in Amerindian women. *American Journal of Clinical Nutrition*, **2006**, 84, 1009-13	7	18

246	Incretins and islet function. *Current Opinion in Endocrinology, Diabetes and Obesity*, **2006**, 13, 154-161		1
245	A novel approach to assess insulin sensitivity reveals no increased insulin sensitivity in mice with a dominant-negative mutant hepatocyte nuclear factor-1alpha. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2006**, 291, R131-7	3.2	5
244	Inhibition of Dipeptidyl Peptidase-4 (DPP-4) - A Novel Approach to Treat Type 2 Diabetes. *Current Enzyme Inhibition*, **2005**, 1, 65-73	0.5	24
243	Assessment of insulin secretion in relation to insulin resistance. *Current Opinion in Clinical Nutrition and Metabolic Care*, **2005**, 8, 529-33	3.8	54
242	Islet adaptation to insulin resistance: mechanisms and implications for intervention. *Diabetes, Obesity and Metabolism*, **2005**, 7, 2-8	6.7	64
241	Sensory nerve desensitization by resiniferatoxin improves glucose tolerance and increases insulin secretion in Zucker Diabetic Fatty rats and is associated with reduced plasma activity of dipeptidyl peptidase IV. *European Journal of Pharmacology*, **2005**, 509, 211-7	5.3	36
240	Beta-cell expression of a dominant-negative HNF-1alpha compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice. *European Journal of Pharmacology*, **2005**, 521, 164-8	5.3	25
239	Comparative evaluation of simple insulin sensitivity methods based on the oral glucose tolerance test. *Diabetologia*, **2005**, 48, 748-51	10.3	74
238	What mediates the benefits associated with dipeptidyl peptidase-IV inhibition?. *Diabetologia*, **2005**, 48, 605-7	10.3	15
237	Alpha cell function in health and disease: influence of glucagon-like peptide-1. *Diabetologia*, **2005**, 48, 1700-13	10.3	221
236	Reduced insulin clearance contributes to the increased insulin levels after administration of glucagon-like peptide 1 in mice. *Diabetologia*, **2005**, 48, 2140-6	10.3	45
235	Type 2 diabetes, insulin secretion and beta-cell mass. *Current Molecular Medicine*, **2005**, 5, 275-86	2.5	105
234	Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. *Diabetes Care*, **2005**, 28, 1936-40	14.6	271
233	Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice. *Endocrinology*, **2005**, 146, 2055-9	4.8	83
232	A 90-day toxicological evaluation of 1,5-anhydro-d-fructose in Sprague-Dawley rats. *Drug and Chemical Toxicology*, **2005**, 28, 263-72	2.3	9
231	Exenatide: a novel treatment of Type 2 diabetes. *Therapy: Open Access in Clinical Medicine*, **2005**, 2, 207-222		19
230	Exenatide: a novel treatment of Type 2 diabetes. *Therapy: Open Access in Clinical Medicine*, **2005**, 2, 207-222		3
229	Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2004**, 286, R269-72	3.2	76

228	Glucagon-like peptide-1 and islet lipolysis. *Hormone and Metabolic Research*, **2004**, 36, 795-803	3.1	21
227	GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. *Hormone and Metabolic Research*, **2004**, 36, 867-76	3.1	187
226	Loss-of-function mutation of the galanin gene is associated with perturbed islet function in mice. *Endocrinology*, **2004**, 145, 3190-6	4.8	63
225	GLP-1 and extra-islet effects. *Hormone and Metabolic Research*, **2004**, 36, 842-5	3.1	53
224	Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. *Diabetes Care*, **2004**, 27, 2874-80	14.6	429
223	Beta-cell-targeted overexpression of phosphodiesterase 3B in mice causes impaired insulin secretion, glucose intolerance, and deranged islet morphology. *Journal of Biological Chemistry*, **2004**, 279, 15214-22	5.4	46
222	Beta-cell-targeted expression of a dominant-negative mutant of hepatocyte nuclear factor-1alpha in mice: diabetes model with beta-cell dysfunction partially rescued by nonglucose secretagogues. *Diabetes*, **2004**, 53 Suppl 3, S92-6	0.9	8
221	Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies. *European Journal of Endocrinology*, **2004**, 150, 97-104	6.5	173
220	Milrinone efficiently potentiates insulin secretion induced by orally but not intravenously administered glucose in C57BL6J mice. *European Journal of Pharmacology*, **2004**, 498, 319-23	5.3	10
219	Correlation of apolipoprotein M with leptin and cholesterol in normal and obese subjects. *Journal of Nutritional Biochemistry*, **2004**, 15, 579-82	6.3	38
218	Enhancement or prolongation of GLP-1 activity as a strategy for treatment of type 2 diabetes. *Drug Discovery Today: Therapeutic Strategies*, **2004**, 1, 207-212		8
217	Body adiposity, insulin, and leptin in subgroups of Peruvian Amerindians. *High Altitude Medicine and Biology*, **2004**, 5, 27-31	1.9	43
216	Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?. *Expert Opinion on Investigational Drugs*, **2004**, 13, 1091-102	5.9	155
215	The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. *Diabetes*, **2004**, 53 Suppl 3, S215-9	0.9	713
214	Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 2078-84	5.6	611
213	Basic toxicology and metabolism studies of 1,5-anhydro-D-fructose using bacteria, cultured mammalian cells, and rodents. *Food and Chemical Toxicology*, **2004**, 42, 1677-86	4.7	19
212	Both leptin and leptin-receptor are essential for apolipoprotein M expression in vivo. *Biochemical and Biophysical Research Communications*, **2004**, 321, 916-21	3.4	50
211	Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance. *Metabolism: Clinical and Experimental*, **2004**, 53, 624-31	12.7	78

210	Increased insulin sensitivity is associated with reduced insulin and glucagon secretion and increased insulin clearance in man. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 1264-70	5.6	25
209	Dual effects of pituitary adenylate cyclase-activating polypeptide and isoproterenol on lipid metabolism and signaling in primary rat adipocytes. *Endocrinology*, **2003**, 144, 5293-9	4.8	30
208	Improved beta-cell function after standardized weight reduction in severely obese subjects. *American Journal of Physiology - Endocrinology and Metabolism*, **2003**, 284, E557-65	6	96
207	Gut peptides and type 2 diabetes mellitus treatment. *Current Diabetes Reports*, **2003**, 3, 365-72	5.6	101
206	Acylation stimulating protein stimulates insulin secretion. *International Journal of Obesity*, **2003**, 27, 1037-43	5.5	46
205	Dose-dependent inhibition by ghrelin of insulin secretion in the mouse. *Endocrinology*, **2003**, 144, 916-21	4.8	237
204	Signals adapting the beta cells to changes in insulin sensitivity. *International Congress Series*, **2003**, 1253, 105-113		1
203	PACAP is expressed in secretory granules of insulin and glucagon cells in human and rodent pancreas. Evidence for generation of cAMP compartments uncoupled from hormone release in diabetic islets. *Regulatory Peptides*, **2003**, 113, 31-9		22
202	Postnatally disturbed pancreatic islet cell distribution in human islet amyloid polypeptide transgenic mice. *Regulatory Peptides*, **2003**, 113, 89-94		8
201	Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans. *Diabetes Care*, **2003**, 26, 2860-4	14.6	66
200	PACAP and the Endocrine Pancreas. *Growth Hormone*, **2003**, 185-206		0
199	Effects of chemical sympathectomy by means of 6-hydroxydopamine on insulin secretion and islet morphology in alloxan-diabetic mice. *Cell and Tissue Research*, **2002**, 307, 203-9	4.2	13
198	The neuropeptide PACAP contributes to the glucagon response to insulin-induced hypoglycaemia in mice. *Acta Physiologica Scandinavica*, **2002**, 175, 25-8		20
197	Autonomic neuropathy is associated with impaired pancreatic polypeptide and neuropeptide Y responses to insulin-induced hypoglycaemia in Type I diabetic patients. *Diabetologia*, **2002**, 45, 1043-4	10.3	11
196	Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. *Diabetes Care*, **2002**, 25, 869-75	14.6	383
195	Abnormal release of incretins and cortisol after oral glucose in subjects with insulin-resistant myotonic dystrophy. *European Journal of Endocrinology*, **2002**, 146, 397-405	6.5	9
194	Islet function phenotype in gastrin-releasing peptide receptor gene-deficient mice. *Endocrinology*, **2002**, 143, 3717-26	4.8	25
193	Quantification of insulin secretion in relation to insulin sensitivity in nondiabetic postmenopausal women. *Diabetes*, **2002**, 51 Suppl 1, S202-11	0.9	35

192	Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. *European Journal of Endocrinology*, **2002**, 146, 717-27	6.5	156
191	Insufficient islet compensation to insulin resistance vs. reduced glucose effectiveness in glucose-intolerant mice. *American Journal of Physiology - Endocrinology and Metabolism*, **2002**, 283, E738-44	6	66
190	Differential impairment of glucagon responses to hypoglycemia, neuroglycopenia, arginine, and carbachol in alloxan-diabetic mice. *Metabolism: Clinical and Experimental*, **2002**, 51, 12-9	12.7	9
189	Differential effects of glucagon-like peptide-1 (7-36)amide versus cholecystokinin on arginine-induced islet hormone release in vivo and in vitro. *Pancreas*, **2001**, 22, 58-64	2.6	13
188	Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations. *Diabetologia*, **2001**, 44, 1998-2003	10.3	75
187	Reducing plasma free fatty acids by acipimox improves glucose tolerance in high-fat fed mice. *Acta Physiologica Scandinavica*, **2001**, 171, 161-7		26
186	Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes. *Journal of Internal Medicine*, **2001**, 250, 81-7	10.8	23
185	The neuropeptide pituitary adenylate cyclase-activating polypeptide and islet function. *Diabetes*, **2001**, 50, 1959-69	0.9	72
184	The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia. *Diabetes*, **2001**, 50, 1030-8	0.9	223
183	Overweight is associated with lower serum leptin in Peruvian Indian than in Caucasian women: A dissociation contributing to low blood pressure?. *Metabolism: Clinical and Experimental*, **2001**, 50, 325-9	12.7	17
182	Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. *Diabetes Care*, **2001**, 24, 1640-5	14.6	172
181	Contribution to glucose tolerance of insulin-independent vs. insulin-dependent mechanisms in mice. *American Journal of Physiology - Endocrinology and Metabolism*, **2001**, 281, E693-703	6	90
180	The effects of PACAP on insulin secretion and glucose disposal are altered by adrenalectomy in mice. *Annals of the New York Academy of Sciences*, **2000**, 921, 251-8	6.5	6
179	Intraperitoneal PACAP administration decreases blood glucose in GK rats, and in normal and high fat diet mice. *Annals of the New York Academy of Sciences*, **2000**, 921, 259-63	6.5	32
178	PACAP27 sensitizes glucose induced insulin secretion in INS-1 cells. *Annals of the New York Academy of Sciences*, **2000**, 921, 456-9	6.5	1
177	Diurnal variation in circulating leptin is dependent on gender, food intake and circulating insulin in mice. *Acta Physiologica Scandinavica*, **2000**, 169, 325-31		69
176	The negative association between serum free testosterone and leptin is dependent on insulin-like growth factor-binding protein 1 in healthy young and middle-aged men. *Clinical Endocrinology*, **2000**, 52, 493-8	3.4	4
175	Pharmacokinetics of human leptin in mice and rhesus monkeys. *International Journal of Obesity*, **2000**, 24, 1579-85	5.5	32

174	Augmented insulinotropic action of arachidonic acid through the lipoxygenase pathway in the obese Zucker rat. *Obesity*, **2000**, 8, 475-80		15
173	1,5-Anhydro-D-fructose increases glucose tolerance by increasing glucagon-like peptide-1 and insulin in mice. *European Journal of Pharmacology*, **2000**, 397, 219-25	5.3	21
172	Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. *European Journal of Pharmacology*, **2000**, 404, 239-45	5.3	153
171	Phospholipase A2 and its potential regulation of islet function. *International Journal of Gastrointestinal Cancer*, **2000**, 27, 1-11		12
170	Glucose intolerance is predicted by low insulin secretion and high glucagon secretion: outcome of a prospective study in postmenopausal Caucasian women. *Diabetologia*, **2000**, 43, 194-202	10.3	58
169	Autonomic regulation of islet hormone secretion--implications for health and disease. *Diabetologia*, **2000**, 43, 393-410	10.3	687
168	Islet amyloid polypeptide (amylin)-deficient mice develop a more severe form of alloxan-induced diabetes. *American Journal of Physiology - Endocrinology and Metabolism*, **2000**, 278, E684-E691	6	27
167	Reduced GLP-1 and insulin responses and glucose intolerance after gastric glucose in GRP receptor-deleted mice. *American Journal of Physiology - Endocrinology and Metabolism*, **2000**, 279, E956-62	6	42
166	PACAP contributes to insulin secretion after gastric glucose gavage in mice. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2000**, 279, R424-32	3.2	21
165	Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance. *Diabetes Care*, **2000**, 23, 650-7	14.6	77
164	Antidiabetogenic action of cholecystokinin-8 in type 2 diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2000**, 85, 1043-8	5.6	56
163	Differential changes in islet amyloid polypeptide (amylin) and insulin mRNA expression after high-fat diet-induced insulin resistance in C57BL/6J mice. *Metabolism: Clinical and Experimental*, **2000**, 49, 1518-22	12.7	19
162	Islet amyloid and type 2 diabetes mellitus. *New England Journal of Medicine*, **2000**, 343, 411-9	59.2	439
161	PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance. *Journal of Clinical Investigation*, **2000**, 105, 1307-15	15.9	149
160	Antidiabetogenic Action of Cholecystokinin-8 in Type 2 Diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2000**, 85, 1043-1048	5.6	56
159	Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice. *American Journal of Physiology - Endocrinology and Metabolism*, **1999**, 277, E996-E1004	6	36
158	Increased insulin secretion and normalization of glucose tolerance by cholinergic agonism in high fat-fed mice. *American Journal of Physiology - Endocrinology and Metabolism*, **1999**, 277, E93-102	6	25
157	Leptin inhibits insulin secretion induced by cellular cAMP in a pancreatic B cell line (INS-1 cells). *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **1999**, 277, R959-66	3.2	24

156	Relative hyperproinsulinemia as a sign of islet dysfunction in women with impaired glucose tolerance. *Journal of Clinical Endocrinology and Metabolism*, **1999**, 84, 2068-74	5.6	40
155	Plasma leptin and insulin in C57Bl/6J mice on a high-fat diet: relation to subsequent changes in body weight. *Acta Physiologica Scandinavica*, **1999**, 165, 233-40		49
154	Lowering of circulating insulin and leptin is closely associated following weight reduction after vertical banded gastroplasty in obese women. *Diabetes, Obesity and Metabolism*, **1999**, 1, 53-5	6.7	11
153	Leptin increases circulating glucose, insulin and glucagon via sympathetic neural activation in fasted mice. *International Journal of Obesity*, **1999**, 23, 660-5	5.5	15
152	Insulin resistant subjects lack islet adaptation to short-term dexamethasone-induced reduction in insulin sensitivity. *Diabetologia*, **1999**, 42, 936-43	10.3	55
151	Relation between malnutrition and development of diabetes mellitus. *International Journal of Gastrointestinal Cancer*, **1999**, 26, 125-30		1
150	Islet neuronal abnormalities associated with impaired insulin secretion in type 2 diabetes in the Chinese hamster. *Regulatory Peptides*, **1999**, 82, 71-9		10
149	Regulation of insulin secretion by nerves and neuropeptides. *Annals of the Academy of Medicine, Singapore*, **1999**, 28, 99-104	2.8	11
148	Protein kinase A inhibition and PACAP-induced insulin secretion in HIT-T15 cells. *Annals of the New York Academy of Sciences*, **1998**, 865, 441-4	6.5	12
147	Pituitary adenylate cyclase activating polypeptide stimulates insulin secretion in a glucose-dependent manner in vivo. *Annals of the New York Academy of Sciences*, **1998**, 865, 466-70	6.5	1
146	Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes. *BioEssays*, **1998**, 20, 642-51	4.1	91
145	Glucose-dependent arginine stimulation test for characterization of islet function: studies on reproducibility and priming effect of arginine. *Diabetologia*, **1998**, 41, 772-7	10.3	81
144	Transgenic overexpression of human islet amyloid polypeptide inhibits insulin secretion and glucose elimination after gastric glucose gavage in mice. *Diabetologia*, **1998**, 41, 1374-80	10.3	35
143	PACAP and PACAP receptors in insulin producing tissues: localization and effects. *Regulatory Peptides*, **1998**, 74, 167-75		55
142	Different sensitivity to the cytotoxic action of IAPP fibrils in two insulin-producing cell lines, HIT-T15 and RINm5F cells. *Biochemical and Biophysical Research Communications*, **1998**, 251, 888-93	3.4	32
141	Potentiated beta-cell response to non-glucose stimuli in insulin-resistant C57BL/6J mice. *European Journal of Pharmacology*, **1998**, 350, 243-50	5.3	26
140	Marked hyperleptinemia after high-fat diet associated with severe glucose intolerance in mice. *European Journal of Endocrinology*, **1998**, 139, 461-7	6.5	80
139	Age-related reduction in glucose elimination is accompanied by reduced glucose effectiveness and increased hepatic insulin extraction in man. *Journal of Clinical Endocrinology and Metabolism*, **1998**, 83, 3350-6	5.6	44

138	Autonomic mediation of glucagon secretion during hypoglycemia: implications for impaired alpha-cell responses in type 1 diabetes. *Diabetes*, **1998**, 47, 995-1005	0.9	174
137	Evidence for contribution by increased cytoplasmic Na+ to the insulinotropic action of PACAP38 in HIT-T15 cells. *Journal of Biological Chemistry*, **1998**, 273, 32602-7	5.4	12
136	Insulin secretion by gastrin-releasing peptide in mice: ganglionic versus direct islet effect. *American Journal of Physiology - Endocrinology and Metabolism*, **1998**, 274, E124-9	6	7
135	PACAP stimulates insulin secretion but inhibits insulin sensitivity in mice. *American Journal of Physiology - Endocrinology and Metabolism*, **1998**, 274, E834-42	6	26
134	Marked and rapid decreases of circulating leptin in streptozotocin diabetic rats: reversal by insulin. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **1998**, 274, R1482-91	3.2	69
133	Age-Related Reduction in Glucose Elimination Is Accompanied by Reduced Glucose Effectiveness and Increased Hepatic Insulin Extraction in Man. *Journal of Clinical Endocrinology and Metabolism*, **1998**, 83, 3350-3356	5.6	31
132	Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. *Journal of Clinical Endocrinology and Metabolism*, **1997**, 82, 473-8	5.6	118
131	Differential effect of insulin treatment on islet amyloid polypeptide (amylin) and insulin gene expression in streptozotocin-induced diabetes in rats. *Journal of Endocrinology*, **1997**, 152, 495-501	4.7	4
130	Pituitary adenylate cyclase-activating polypeptide stimulates insulin and glucagon secretion in humans. *Journal of Clinical Endocrinology and Metabolism*, **1997**, 82, 3093-8	5.6	64
129	Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance. *European Journal of Endocrinology*, **1997**, 137, 127-31	6.5	42
128	GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions. *Diabetes Care*, **1997**, 20, 1874-9	14.6	73
127	Activation of autonomic nerves and the adrenal medulla contributes to increased glucagon secretion during moderate insulin-induced hypoglycemia in women. *Diabetes*, **1997**, 46, 801-7	0.9	71
126	No correlation between insulin and islet amyloid polypeptide after stimulation with glucagon-like peptide-1 in type 2 diabetes. *European Journal of Endocrinology*, **1997**, 137, 643-9	6.5	7
125	Galanin exerts dual action on inositol-specific phospholipase C activity in isolated pancreatic islets. *Endocrine Journal*, **1997**, 44, 283-8	2.9	3
124	Dissociated insulinotropic sensitivity to glucose and carbachol in high-fat diet-induced insulin resistance in C57BL/6J mice. *Metabolism: Clinical and Experimental*, **1997**, 46, 97-106	12.7	111
123	Impaired adaptation of first-phase insulin secretion in postmenopausal women with glucose intolerance. *American Journal of Physiology - Endocrinology and Metabolism*, **1997**, 273, E701-7	6	21
122	Regulation of plasma leptin in mice: influence of age, high-fat diet, and fasting. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **1997**, 273, R113-20	3.2	96
121	Regulation of circulating leptin in humans. *Endocrine*, **1997**, 7, 1-8		53

120	Function of reduced-size liver transplant in the rat. *Research in Experimental Medicine*, **1997**, 197, 91-9		1
119	Intraoperative secretion of intact parathyroid hormone and amino-terminal parathyroid hormone fragments from normal parathyroid glands associated with solitary parathyroid adenoma. *World Journal of Surgery*, **1997**, 21, 30-4; discussion 34-5	3.3	5
118	Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. *Acta Physiologica Scandinavica*, **1997**, 160, 413-22		94
117	Effects of Glucagon-Like Peptide-1 on Islet Function and Insulin Sensitivity in Noninsulin-Dependent Diabetes Mellitus. *Journal of Clinical Endocrinology and Metabolism*, **1997**, 82, 473-478	5.6	100
116	Activation of autonomic nerves and the adrenal medulla contributes to increased glucagon secretion during moderate insulin-induced hypoglycemia in women. *Diabetes*, **1997**, 46, 801-807	0.9	16
115	Peptide YY does not inhibit glucose-stimulated insulin secretion in humans. *European Journal of Endocrinology*, **1996**, 134, 362-5	6.5	23
114	Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet. *Diabetes Care*, **1996**, 19, 843-8	14.6	101
113	Signaling mechanisms underlying the insulinotropic effect of pituitary adenylate cyclase-activating polypeptide in HIT-T15 cells. *Endocrinology*, **1996**, 137, 2791-8	4.8	41
112	Islet dysfunction in obese women with impaired glucose tolerance. *Metabolism: Clinical and Experimental*, **1996**, 45, 502-9	12.7	37
111	Effects of glucagon-like peptide-I on glucose turnover in rats. *American Journal of Physiology - Endocrinology and Metabolism*, **1996**, 270, E1015-21	6	11
110	Stimulation of somatostatin secretion by 3-O-methylglucose in the perfused dog pancreas. *International Journal of Gastrointestinal Cancer*, **1996**, 20, 103-7		3
109	Glucagon-like peptide-1(7-36)amide and cytoplasmic calcium in insulin producing cells. *Acta Physiologica Scandinavica*, **1996**, 157, 333-41		4
108	Pancreastatin modulates glucose-stimulated insulin secretion from the perfused rat pancreas. *Acta Physiologica Scandinavica*, **1996**, 158, 63-70		11
107	Failure to adequately adapt reduced insulin sensitivity with increased insulin secretion in women with impaired glucose tolerance. *Diabetologia*, **1996**, 39, 1099-107	10.3	54
106	Blockade of muscarinic transmission increases the frequency of diabetes after low-dose alloxan challenge in the mouse. *Diabetologia*, **1996**, 39, 383-90	10.3	13
105	Plasma neuropeptide Y in impaired glucose tolerance. *Acta Diabetologica*, **1996**, 33, 295-7	3.9	1
104	Islet amyloid polypeptide (amylin) and insulin are differentially expressed in chronic diabetes induced by streptozotocin in rats **1996**, 39, 649		1
103	Failure to adequately adapt reduced insulin sensitivity with increased insulin secretion in women with impaired glucose tolerance **1996**, 39, 1099		5

102	Blockade of muscarinic transmission increases the frequency of diabetes after low-dose alloxan challenge in the mouse. *Diabetologia*, **1996**, 39, 383-390	10.3	
101	Long-term effects of alloxan in mice. *International Journal of Gastrointestinal Cancer*, **1995**, 17, 197-201		14
100	Antidiabetogenic action of truncated glucagon-like peptide-1 in mice. *Endocrine*, **1995**, 3, 367-9		4
99	Effects of minor increase in serum calcium on the immunoheterogeneity of parathyroid hormone in healthy subjects and in patients with primary hyperparathyroidism. *Hormone Research*, **1995**, 43, 294-9		1
98	Glucose modulation of insulin and glucagon secretion is altered in impaired glucose tolerance. *Journal of Clinical Endocrinology and Metabolism*, **1995**, 80, 1778-82	5.6	33
97	Differential expression of islet amyloid polypeptide (amylin) and insulin in experimental diabetes in rodents. *Molecular and Cellular Endocrinology*, **1995**, 114, 101-9	4.4	32
96	Effects of GLP-1 and 2,5-anhydro-D-mannitol on insulin secretion and plasma glucose in mice. *Endocrine Research*, **1995**, 21, 583-94	1.9	9
95	Effects of arginine on the secretion of insulin and islet amyloid polypeptide in humans. *Pancreas*, **1995**, 11, 201-5	2.6	15
94	Fasting blood glucose in determining the prevalence of diabetes in a large, homogeneous population of Caucasian middle-aged women. *Journal of Internal Medicine*, **1995**, 237, 537-41	10.8	48
93	Insulinotropic action of truncated glucagon-like peptide-1 in mice. *Acta Physiologica Scandinavica*, **1995**, 153, 205-6		24
92	Glucagon secretory response to hypoglycaemia, adrenaline and carbachol in streptozotocin-diabetic rats. *Acta Physiologica Scandinavica*, **1995**, 155, 215-21		15
91	Non-parallelism of islet amyloid polypeptide (amylin) and insulin gene expression in rat islets following dexamethasone treatment. *Diabetologia*, **1995**, 38, 395-402	10.3	3
90	Involvement of capsaicin-sensitive nerves in regulation of insulin secretion and glucose tolerance in conscious mice. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **1994**, 267, R1071-7	3.2	21
89	Mechanisms underlying the insulinostatic effect of peptide YY in mouse pancreatic islets. *Diabetologia*, **1994**, 37, 871-878	10.3	
88	Different mechanisms are involved in neuropeptide Y-induced pancreatic vasoconstriction and inhibition of insulin secretion. *European Journal of Pharmacology*, **1993**, 236, 69-74	5.3	16
87	Potential clinical use of the EDTA-infusion test. *Clinical Chemistry and Laboratory Medicine*, **1993**, 31, 353-8	5.9	
86	Muscarinic receptor subtypes in carbachol-stimulated insulin and glucagon secretion in the mouse. *Autonomic and Autacoid Pharmacology*, **1993**, 13, 439-446		17
85	Interferon-alpha in the treatment of neuroendocrine tumours: effect on glucose tolerance and glucose-stimulated insulin secretion. *The European Journal of Surgery*, **1993**, 159, 209-12		2

84	Capacity to secrete islet hormones after subtotal pancreatectomy for pancreatic cancer. *The European Journal of Surgery*, **1993**, 159, 223-7		12
83	CHOLECYSTOKININ (CCK 33) CAN STIMULATE PANCREATIC SECRETION BY A LOCAL INTESTINAL MECHANISM IN THE PIG . *Biomedical Research*, **1993**, 14, 217-221	1.5	11
82	Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. *New England Journal of Medicine*, **1992**, 326, 1316-22	59.2	764
81	Cholecystokinin and the regulation of insulin secretion. *Scandinavian Journal of Gastroenterology*, **1992**, 27, 161-5	2.4	48
80	Plasma neuropeptide Y (NPY) and galanin before and during exercise in type 1 diabetic patients with autonomic dysfunction. *Diabetes Research and Clinical Practice*, **1992**, 15, 219-26	7.4	19
79	Inhibitory effect of D-myo-inositol-1,2,6-trisphosphate on glucose-stimulated insulin secretion in the mouse. *Neuropeptides*, **1992**, 21, 163-6	3.3	6
78	Neonatal capsaicin-treatment in mice: effects on pancreatic peptidergic nerves and 2-deoxy-D-glucose-induced insulin and glucagon secretion. *Journal of the Autonomic Nervous System*, **1992**, 39, 51-9		30
77	Pituitary adenylate cyclase-activating polypeptide (PACAP): occurrence in rodent pancreas and effects on insulin and glucagon secretion in the mouse. *Cell and Tissue Research*, **1992**, 269, 275-9	4.2	114
76	Localization of calcitonin gene-related peptide and islet amyloid polypeptide in the rat and mouse pancreas. *Cell and Tissue Research*, **1992**, 269, 315-22	4.2	38
75	Galanin inhibits tolbutamide-stimulated insulin secretion in the perfused pig pancreas. *Diabetes Research*, **1992**, 19, 59-62		
74	Recurrent laryngeal nerve palsy after thyroid and parathyroid surgery. Experience from Lund University. *Thyroidology*, **1992**, 4, 87-9		2
73	Treatment of malignant midgut carcinoid with a highly purified human leukocyte alpha-interferon. *Anticancer Research*, **1992**, 12, 129-33	2.3	11
72	Tolerance to long-term treatment of malignant midgut carcinoid with a highly purified human leukocyte alpha-interferon. *Anticancer Research*, **1992**, 12, 881-4	2.3	6
71	GLP-1 and GLP-17-36 Amide. *Pancreas*, **1991**, 6, 208-215	2.6	56
70	Presence of galanin in human pancreatic nerves and inhibition of insulin secretion from isolated human islets. *Cell and Tissue Research*, **1991**, 264, 263-7	4.2	42
69	Galanin-immunoreactive nerves in the mouse and rat pancreas. *Cell and Tissue Research*, **1991**, 264, 363-8	4.2	42
68	Contribution of galanin to stress-induced impairment of insulin secretion in swimming mice. *Acta Physiologica Scandinavica*, **1991**, 143, 145-52		16
67	Inhibition by galanin and by high K+ of human basophil histamine release triggered by calcium ionophores but not responses induced by anti-IgE, chemotactic peptide or phorbol ester. *British Journal of Pharmacology*, **1991**, 103, 1381-4	8.6	1

66	Effects of helospectin I on insulin and glucagon secretion in the mouse. *British Journal of Pharmacology*, **1991**, 102, 916-8	8.6	4
65	Effects of amidated rat islet amyloid polypeptide on glucose-stimulated insulin secretion in vivo and in vitro in rats. *European Journal of Pharmacology*, **1991**, 192, 443-5	5.3	27
64	Studies on the mechanism by which galanin inhibits insulin secretion in islets. *European Journal of Pharmacology*, **1991**, 205, 21-7	5.3	23
63	Effects of neuropeptide Y on insulin and glucagon secretion in the pig. *Neuropeptides*, **1991**, 20, 49-55	3.3	9
62	Effects of cholecystokinin (CCK)-8, CCK-33, and gastric inhibitory polypeptide (GIP) on basal and meal-stimulated pancreatic hormone secretion in man. *Diabetes Research and Clinical Practice*, **1991**, 13, 153-61	7.4	44
61	Regulatory peptides in the thyroid gland--a review on their localization and function. *Acta Endocrinologica*, **1991**, 124, 225-32		12
60	GLP-1 and GLP-1(7-36) amide: influences on basal and stimulated insulin and glucagon secretion in the mouse. *Pancreas*, **1991**, 6, 208-15	2.6	15
59	Galanin of the homologous species inhibits insulin secretion in the rat and in the pig. *Acta Physiologica Scandinavica*, **1990**, 139, 591-6		33
58	Calcitonin gene-related peptide (CGRP) and amylin and the endocrine pancreas. *International Journal of Gastrointestinal Cancer*, **1990**, 6, 1-15		16
57	Galanin is co-localized with noradrenaline and neuropeptide Y in dog pancreas and celiac ganglion. *Cell and Tissue Research*, **1990**, 261, 49-58	4.2	75
56	Subtotal pancreatectomy with stapling the pancreatic remnant. *Langenbecks Archiv Fur Chirurgie*, **1990**, 375, 359-61		1
55	Effects of galanin and calcitonin gene-related peptide on insulin and glucagon secretion in man. *European Journal of Endocrinology*, **1990**, 123, 591-597	6.5	23
54	Effects of galanin and calcitonin gene-related peptide on insulin and glucagon secretion in man. *Acta Endocrinologica*, **1990**, 123, 591-7		8
53	Pancreastatin inhibits insulin secretion and exocrine pancreatic secretion in the pig. *Diabetes Research*, **1990**, 14, 93-6		3
52	Calcium stimulates the release of calcitonin gene-related peptide from the canine thyroid. *American Journal of Physiology - Endocrinology and Metabolism*, **1989**, 256, E597-9	6	
51	Cysteamine and the endocrine pancreas: immunocytochemical, immunochemical, and functional aspects. *Cell and Tissue Research*, **1989**, 256, 159-66	4.2	4
50	Effects of beta-endorphin, met-enkephalin, and dynorphin A on basal and stimulated insulin secretion in the mouse. *International Journal of Gastrointestinal Cancer*, **1989**, 5, 165-78		13
49	Effects of galanin on insulin and glucagon secretion in the rat. *International Journal of Gastrointestinal Cancer*, **1989**, 4, 335-44		21

48	Effects of calcitonin, katacalcin, and calcitonin gene-related peptide on basal and TSH-stimulated thyroid hormone secretion in the mouse. *Acta Physiologica Scandinavica*, **1989**, 135, 133-7		13
47	Effects of VIP and helodermin on thyroid hormone secretion in the mouse. *Neuropeptides*, **1989**, 13, 59-64	3.3	12
46	GABA inhibits thyroid hormone secretion in the mouse. *Thyroidology*, **1989**, 1, 105-8		4
45	Insulin secretion in neonatally streptozotocin-injected mice. *Diabetes Research*, **1989**, 11, 185-9		2
44	Reduction of secretion from a small-bowel fistula by somatostatin. Case report. *Acta Chirurgica Scandinavica*, **1989**, 155, 205-8		1
43	Effects of gastrin-releasing peptide on basal and stimulated thyroid hormone secretion in the mouse. *Acta Endocrinologica*, **1989**, 120, 245-9		
42	Treatment of pancreatic fistula with the somatostatin analogue SMS 201-995. *British Journal of Surgery*, **1988**, 75, 718	5.3	29
41	Cholecystokinin (CCK)-33 stimulates insulin secretion from the perfused rat pancreas: studies on the structure-activity relationship. *Basic and Clinical Pharmacology and Toxicology*, **1988**, 63, 42-5		15
40	Effects of pancreatic noradrenaline infusion on basal and stimulated islet hormone secretion in the dog. *Acta Physiologica Scandinavica*, **1988**, 132, 143-50		9
39	The effects of epinephrine on islet hormone secretion in the dog. *International Journal of Gastrointestinal Cancer*, **1988**, 3, 375-88		4
38	Galanin and the endocrine pancreas. *FEBS Letters*, **1988**, 229, 233-7	3.8	51
37	Pancreastatin inhibits insulin secretion and stimulates glucagon secretion in mice. *Diabetes*, **1988**, 37, 281-5	0.9	61
36	ANF inhibits glucose-stimulated insulin secretion in mouse and rat. *American Journal of Physiology - Endocrinology and Metabolism*, **1988**, 255, E579-82	6	5
35	Plasmapheresis and haemodialysis in a case of septic cholangitis complicated by hepatic and renal failure. Case report. *Acta Chirurgica Scandinavica*, **1988**, 154, 157-9		3
34	Insulin and C-peptide secretory responses to glucagon in man: studies on the dose-response relationships. *Acta Medica Scandinavica*, **1987**, 221, 185-90		18
33	Sympathetic nerve stimulation versus pancreatic norepinephrine infusion in the dog: 1). Effects on basal release of insulin and glucagon. *Endocrinology*, **1987**, 121, 323-31	4.8	111
32	Alpha-adrenoceptor blockade by phentolamine inhibits beta-adrenergically and cholinergically induced glucagon secretion in the mouse. *Hormone and Metabolic Research*, **1987**, 19, 600-3	3.1	10
31	The mechanism of 2-deoxy-glucose-induced insulin secretion in the mouse. *Autonomic and Autacoid Pharmacology*, **1987**, 7, 135-44		21

30	Gastrin releasing peptide (GRP): effects on basal and stimulated insulin and glucagon secretion in the mouse. *Peptides*, **1987**, 8, 55-60	3.8	34
29	Inhibition of 2-deoxy-glucose-induced glucagon secretion by muscarinic and alpha-adrenoceptor blockade in the mouse. *Diabetes Research and Clinical Practice*, **1987**, 3, 239-42	7.4	12
28	Neuropeptide Y: intrapancreatic neuronal localization and effects on insulin secretion in the mouse. *Cell and Tissue Research*, **1987**, 248, 43-8	4.2	98
27	Kinetics of radioiodine released from prelabelled thyroid gland in vivo: influence of propylthiouracil. *Basic and Clinical Pharmacology and Toxicology*, **1987**, 61, 69-71		4
26	Galanin: effects on basal and stimulated insulin and glucagon secretion in the mouse. *Acta Physiologica Scandinavica*, **1987**, 129, 305-9		60
25	Hyperthyroidism and glucose intolerance. *Acta Medica Scandinavica*, **1986**, 220, 5-14		8
24	Effects of six cholecystokinin (CCK) fragments on insulin secretion in the mouse. *Acta Pharmacologica Et Toxicologica*, **1986**, 58, 115-20		13
23	Effects of alpha 1- and alpha 2-adrenoceptor stimulation and blockade on plasma insulin levels in the mouse. *Pancreas*, **1986**, 1, 415-20	2.6	30
22	Neuropeptidergic versus cholinergic and adrenergic regulation of islet hormone secretion. *Diabetologia*, **1986**, 29, 827-36	10.3	254
21	Potentiation of glucose-induced insulin secretion in the perfused rat pancreas by porcine GIP (gastric inhibitory polypeptide), bovine GIP, and bovine GIP(1-39). *Acta Physiologica Scandinavica*, **1986**, 127, 323-6		10
20	The mechanism of vagal nerve stimulation of glucagon and insulin secretion in the dog. *Endocrinology*, **1986**, 118, 1551-7	4.8	101
19	Effects of alpha- and beta-adrenoceptor stimulation on 45Ca2+ efflux and insulin secretion from perfused rat islets. *Acta Physiologica Scandinavica*, **1985**, 124, 381-9		9
18	Effects of alpha-adrenoceptor blockade by phentolamine on basal and stimulated insulin secretion in the mouse. *Acta Physiologica Scandinavica*, **1985**, 125, 211-7		31
17	Effect of dietary fibre on blood glucose, plasma immunoreactive insulin, C-peptide and GIP responses in non insulin dependent (type 2) diabetics and controls. *Acta Medica Scandinavica*, **1984**, 215, 205-13		33
16	Effect of sulfonylurea on glucose, insulin and C-peptide responses to a meal stimulus in a patient with type 2 diabetes and liver disease. *Acta Medica Scandinavica*, **1984**, 215, 487-91		1
15	Interaction of gastric inhibitory polypeptide (GIP) and cholecystokinin (CCK-8) with basal and stimulated insulin secretion in mice. *European Journal of Endocrinology*, **1983**, 102, 96-102	6.5	30
14	Influences of gastro-intestinal polypeptides and glucose on glucagon secretion induced by cholinergic stimulation. *Hormone and Metabolic Research*, **1982**, 14, 529-32	3.1	14
13	Modulation of basal insulin secretion in the obese, hyperglycemic mouse. *Metabolism: Clinical and Experimental*, **1982**, 31, 172-9	12.7	28

12	VIP-stimulated thyroid hormone secretion: effects of other neuropeptides and alpha- or beta-adrenoceptor blockade. *Acta Physiologica Scandinavica*, **1982**, 114, 471-3		21
11	Enhancement of insulin secretion during selective blockade of alpha 1- and alpha 2-adrenoceptors in the rat: effects of somatostatin. *Acta Physiologica Scandinavica*, **1982**, 115, 257-60		11
10	Glucagon immunoreactivity in plasma from normal and dystrophic mice. *Diabetologia*, **1982**, 22, 258-63	10.3	65
9	Immunoreactive insulin and C-peptide responses to various insulin secretory stimuli in subjects with type 2 diabetes and in control subjects during continuous glucose monitoring. *Acta Medica Scandinavica*, **1981**, 210, 337-48		12
8	Effects of autonomic blockade by methylatropine and optical isomers and propranolol on plasma insulin levels in the basal state and after stimulation. *Acta Physiologica Scandinavica*, **1981**, 112, 57-63		26
7	GIP-like immunoreactivity in glucagon cells. Interactions between GIP and glucagon on insulin release. *Acta Physiologica Scandinavica*, **1981**, 112, 233-42		24
6	Insulin secretion induced by glucose and by stimulation of beta 2 -adrenoceptors in the rat. Different sensitivity to somatostatin. *Acta Physiologica Scandinavica*, **1981**, 112, 421-6		6
5	Adrenalectomy and chemical sympathectomy by 6-hydroxydopamine. Effects on basal and stimulated insulin secretion. *Pflugers Archiv European Journal of Physiology*, **1981**, 390, 17-21	4.6	8
4	Effects of vasoactive intestinal polypeptide (VIP), secretin and gastrin on insulin secretion in the mouse. *Diabetologia*, **1981**, 21, 54-59	10.3	2
3	Effects of glucagon and pentagastrin on glibenclamide-induced insulin release. *Acta Physiologica Scandinavica*, **1980**, 109, 261-4		1
2	Somatostatin, pancreatic polypeptide, substance P, and neurotensin: cellular distribution and effects on stimulated insulin secretion in the mouse. *Endocrinology*, **1979**, 104, 832-8	4.8	68
1	Failure of somatostatin to eliminate the glucagon release induced by baroreceptor unloading in the cat. *Acta Physiologica Scandinavica*, **1978**, 103, 478-80		4